Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Total Non-Current Liabilities (2021 - 2026)

Indivior Pharmaceuticals has reported Total Non-Current Liabilities over the past 6 years, most recently at $1.3 billion for Q1 2026.

  • For Q1 2026, Total Non-Current Liabilities fell 19.66% year-over-year to $1.3 billion; the TTM value through Mar 2026 reached $1.3 billion, down 19.66%, while the annual FY2025 figure was $1.3 billion, 21.73% down from the prior year.
  • Total Non-Current Liabilities for Q1 2026 was $1.3 billion at Indivior Pharmaceuticals, up from $1.3 billion in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $1.7 billion in Q2 2025 and troughed at -$1.5 billion in Q3 2023.
  • A 5-year average of $305.2 million and a median of $699.0 million in 2022 define the central range for Total Non-Current Liabilities.
  • On a YoY basis, Total Non-Current Liabilities climbed as much as 245.4% in 2025 and fell as far as 21.73% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $699.0 million in 2022, then fell by 7.15% to $649.0 million in 2023, then skyrocketed by 151.77% to $1.6 billion in 2024, then decreased by 21.73% to $1.3 billion in 2025, then increased by 3.21% to $1.3 billion in 2026.
  • Business Quant data shows Total Non-Current Liabilities for INDV at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.6 billion in Q3 2025.